Sumitomo Mitsui Trust Group’s NovoCure NVCR Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-232,435	Closed	-$9.65M	–	1155
2023 Q2	$9.65M	Sell	232,435 -35,580	-13%	-$2.21M	0.01%	792
2023 Q1	$16.1M	Buy	268,015 +1,371	+0.5%	+$110K	0.01%	743
2022 Q4	$19.6M	Sell	266,644 -3,581	-1%	-$269K	0.02%	717
2022 Q3	$20.5M	Buy	270,225 +3,448	+1%	+$269K	0.02%	698
2022 Q2	$18.5M	Buy	266,777 +8,933	+3%	+$673K	0.01%	728
2022 Q1	$21.4M	Buy	+257,844	New	+$19M	0.01%	717

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Sumitomo Mitsui Trust Group's NVCR Position: Q3 2023 in Review

Sumitomo Mitsui Trust Group sold out of NovoCure (NVCR) in Q3 2023, closing a stake of 232,435 shares — an estimated $9.65M sold.

Sumitomo Mitsui Trust Group first reported a position in NVCR in Q1 2022 and held it in 6 quarters. The position peaked at $21.4M in Q1 2022. 226 funds tracked by Wall St. Rank hold NVCR as of Q3 2023.

Sumitomo Mitsui Trust Group reported no remaining NovoCure position as of Q3 2023 after selling out during the quarter.
Sumitomo Mitsui Trust Group sold 232,435 NovoCure shares in Q3 2023, an estimated $9.65M.
Sumitomo Mitsui Trust Group first reported a position in NovoCure in Q1 2022 and held it in 6 quarters.
Sumitomo Mitsui Trust Group's NovoCure position peaked at $21.4M in Q1 2022.
226 funds tracked by Wall St. Rank held NovoCure as of Q3 2023.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q3 2023, filed 30 Oct 2023.